Early Schedule II Refill With PDMP Red Flags

No - a valid prescription is a legal prerequisite, not a mandate to fill.

• The pharmacist shares corresponding responsibility for ensuring the prescription is for a legitimate medical purpose in the usual course of professional practice (21 CFR 1306.04(a)). That duty cannot be delegated to the prescriber.
• The red flags are cumulative and substantial: three prescribers and multiple pharmacies in about 60 days, an early refill request, a concurrent benzodiazepine, a long travel deadline, and a prescriber who cannot be reached.
• The pharmacist should query the Pennsylvania PDMP, review the full controlled-substance history, calculate approximate morphine milligram equivalents, and attempt to verify the diagnosis, functional goals, and the reason for the early fill with the prescriber. All attempts should be documented with date, time, and names.
• If the red flags cannot be resolved before closing, the pharmacist should not fill and may return the prescription to the patient. There is no legal obligation to dispense, and the insurance rejection is not the legal test.
• Offering naloxone and documenting the refusal is appropriate. Filling because the prescription 'looks valid' or because the patient is traveling would be difficult to defend.

A partial fill is lawful in limited circumstances, but it is not a solution to unresolved red flags.

• Federal law permits a partial fill of a Schedule II prescription at the patient's request or the prescriber's request, with the remainder supplied within 30 days of the date the prescription was written. The pharmacist must record the quantity dispensed, the date, and the dispensing pharmacist. After 30 days, the remainder may not be dispensed.
• A separate rule allows a partial fill when the pharmacy is unable to supply the full quantity; the remainder must generally be supplied within 72 hours.
• Here, the request is driven by an early-refill and travel problem, not by a supply shortage. A partial fill does not cure the underlying obligation to resolve the red flags. The pharmacist must still verify the prescription and exercise corresponding responsibility.
• If the concerns remain unresolved, the correct answer is to decline the fill entirely, not to dispense 30 tablets as a compromise. If the concerns are resolved, a documented partial fill may be reasonable, but the pharmacist should document the rationale and counsel on sedation and respiratory risk.

A physician's assurance helps, but it does not automatically discharge the pharmacist's independent duty.

• The pharmacist should ask specific, documented questions: What is the diagnosis? What function is being treated? What non-opioid and opioid trials have occurred? Is the prescriber aware of the other prescribers, pharmacies, and the alprazolam? Why is an 18-day early fill being authorized?
• The pharmacist should record the prescriber's name, the date and time of the call, the information provided, and the advice given.
• If the answers are coherent and the prescriber accepts responsibility after being fully informed, the pharmacist may exercise professional judgment to fill, with documentation of the rationale, counseling on overdose risk, and an offer of naloxone. A limited partial fill may be a reasonable middle ground.
• If the answers are evasive or inconsistent, the pharmacist may still refuse. The corresponding responsibility doctrine is designed for exactly this situation, and 'the doctor said to fill it' is not a defense to a knowingly improper dispensing.